Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Nyxoah SA NYXH

Healthcare  —  Medical Instruments & Supplies
1.45 0.18 14.17% as of 25 Sep
Market cap
$129.3M
P/E
0.0×
Revenue Champion (5y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Nyxoah SA (NYXH) Business Profile

Updated before January 2025

Company Overview

Nyxoah SA (NASDAQ: NYXH) is a Belgium-based medical technology company specializing in innovative solutions for the treatment of Obstructive Sleep Apnea (OSA). Founded in 2009 by Robert Taub, Nyxoah has established itself as a pioneer in the field of neurostimulation technology. The company’s mission is to improve the quality of life for patients suffering from sleep-disordered breathing conditions. Nyxoah’s headquarters are located in Mont-Saint-Guibert, Belgium, with additional offices and operations in the United States and other global markets. The company is led by a team of experienced executives, including Olivier Taelman, who serves as the Chief Executive Officer (CEO), and other key leaders with extensive backgrounds in medical technology and healthcare innovation.

Core Business Segments

Nyxoah focuses on the development and commercialization of cutting-edge medical devices designed to address unmet needs in the treatment of Obstructive Sleep Apnea. The company’s primary product offering is the Genio® system, a minimally invasive neurostimulation device.

Genio® System

The Genio® system is Nyxoah’s flagship product and represents a breakthrough in the treatment of moderate to severe Obstructive Sleep Apnea. Unlike traditional Continuous Positive Airway Pressure (CPAP) devices, the Genio® system is a patient-centric solution that uses bilateral hypoglossal nerve stimulation to maintain an open airway during sleep. Key features of the Genio® system include:

  • Minimally Invasive Design: The device is implanted through a single incision, reducing recovery time and improving patient comfort.
  • Battery-Free Technology: The system is powered externally, eliminating the need for battery replacements and reducing maintenance.
  • Customizable Therapy: The device can be tailored to individual patient needs, ensuring optimal therapeutic outcomes.

Nyxoah also provides comprehensive support services to healthcare providers and patients, including training, education, and post-implantation care.

Business Model

Nyxoah operates on a business-to-business (B2B) model, partnering with healthcare providers, hospitals, and sleep clinics to deliver its innovative solutions. The company generates revenue through the sale of its Genio® system and related services. Nyxoah’s business model is built on the following pillars:

  • Product Innovation: Continuous investment in research and development to enhance the Genio® system and expand its applications.
  • Clinical Evidence: Conducting rigorous clinical trials to demonstrate the safety and efficacy of its products, thereby gaining regulatory approvals and market acceptance.
  • Global Expansion: Establishing a presence in key markets, including Europe, the United States, and Asia-Pacific, to drive adoption of its technology.
  • Customer Support: Providing end-to-end support to healthcare providers and patients to ensure successful outcomes.

Strategic Direction

Nyxoah is committed to advancing its position as a leader in the treatment of Obstructive Sleep Apnea. The company’s strategic priorities include:

  • Market Expansion: Nyxoah aims to expand its footprint in the United States, where it recently received FDA Breakthrough Device Designation for the Genio® system. The company is also targeting growth in Europe and Asia-Pacific.
  • Product Development: Nyxoah is investing in the development of next-generation neurostimulation technologies to address additional sleep-disordered breathing conditions and other medical needs.
  • Sustainability Goals: The company is focused on minimizing its environmental impact by adopting sustainable manufacturing practices and reducing waste.
  • Partnerships and Collaborations: Nyxoah is exploring strategic partnerships with healthcare organizations and research institutions to accelerate innovation and market penetration.

Competitive Landscape

Nyxoah operates in a competitive market that includes both traditional and innovative solutions for the treatment of Obstructive Sleep Apnea. Key competitors include:

  • Inspire Medical Systems: A leading provider of implantable neurostimulation devices for sleep apnea.
  • ResMed: A global leader in CPAP devices and other sleep therapy solutions.
  • Philips Respironics: A major player in the sleep and respiratory care market, offering a range of CPAP and BiPAP devices.
  • Itamar Medical: Specializes in home sleep apnea testing and monitoring solutions.

Nyxoah differentiates itself through its unique technology, patient-centric approach, and focus on minimally invasive solutions.

Risk Factors

Despite its innovative technology and growth potential, Nyxoah faces several risks that could impact its business:

  • Regulatory Challenges: Obtaining and maintaining regulatory approvals in different markets can be time-consuming and costly.
  • Market Dependence: The company’s revenue is heavily reliant on the success of the Genio® system, making it vulnerable to market fluctuations and competitive pressures.
  • Supply Chain Disruptions: Global supply chain issues could affect the availability of components and delay product deliveries.
  • Reimbursement Policies: Changes in healthcare reimbursement policies could impact the affordability and adoption of Nyxoah’s products.
  • Technological Competition: Advances in alternative treatments for sleep apnea could pose a threat to Nyxoah’s market position.

Recent Developments

Nyxoah has made significant progress in recent years, including:

  • FDA Breakthrough Device Designation: The Genio® system received this designation, highlighting its potential to address unmet medical needs in the United States.
  • Clinical Trial Success: Positive results from clinical studies have demonstrated the safety and efficacy of the Genio® system, paving the way for regulatory approvals and market adoption.
  • Strategic Partnerships: Nyxoah has entered into collaborations with leading healthcare providers and research institutions to expand its reach and accelerate innovation.
  • Global Expansion: The company has established a presence in new markets, including Asia-Pacific, to drive growth and diversify its revenue streams.

Investment Considerations

Investors considering Nyxoah as a potential investment should weigh the following factors:

Strengths

  • Innovative Technology: The Genio® system offers a unique, minimally invasive solution for Obstructive Sleep Apnea.
  • Growing Market: The global sleep apnea market is expected to grow significantly, driven by increasing awareness and diagnosis rates.
  • Regulatory Approvals: Recent FDA and European approvals position Nyxoah for growth in key markets.
  • Experienced Leadership: The company is led by a team of seasoned executives with a track record of success in medical technology.

Risks

  • Market Dependence: Heavy reliance on the Genio® system for revenue.
  • Competitive Pressure: Intense competition from established players in the sleep apnea market.
  • Regulatory and Reimbursement Risks: Potential challenges in obtaining approvals and securing reimbursement for its products.
  • Supply Chain Vulnerabilities: Dependence on global supply chains for components and manufacturing.

Conclusion

Nyxoah SA is a promising player in the medical technology sector, offering innovative solutions for the treatment of Obstructive Sleep Apnea. With its groundbreaking Genio® system, the company is well-positioned to capitalize on the growing demand for effective sleep apnea treatments. While challenges remain, including regulatory hurdles and competitive pressures, Nyxoah’s focus on innovation, market expansion, and patient-centric solutions provides a strong foundation for future growth. Investors should carefully consider the company’s strengths and risks when evaluating its potential as an investment opportunity.